Patient characteristics and assignment to different dose levels with respect to treatment response
| Characteristic . | Responders (n = 17) . | Nonresponders (n = 21) . |
|---|---|---|
| Median age (range), y | 62 (40-80) | 60 (41-76) |
| Males, n (%) | 15 (88.2) | 15 (71.4) |
| Prior therapy/disease status | ||
| Median no. of prior treatment regimens (range) | 2 (1-4) | 3 (1-6) |
| Refractory to last line of therapy, n (%) | 3 (17.6) | 13 (61.9) |
| Histology, n (%) | ||
| FL | 10 (58.8) | 8 (38.1) |
| MCL | 6 (35.3) | 7 (33.3) |
| DLBCL | 1 (5.9) | 4 (19.0) |
| Other (1 immunocytoma, 1 marginal zone lymphoma) | 0 | 2 (9.5) |
| Dose level, µg/m2per d | ||
| 5 | 0 | 2 |
| 15 | 1 | 8 |
| 30 | 0 | 2 |
| 60 | 14 | 8 |
| 90 | 2 | 1 |
| Treated at target dose, n (%), µg/m2 per d | ||
| <60 | 1 (5.9) | 12 (57.1) |
| ≥60 | 16 (94.1) | 9 (42.9) |
| Median treatment duration (range), d | 57 (4-85) | 31 (1-87) |
| Median no. of treatment cycles (range) | 1 (1-2) | 1 (1-3) |
| Characteristic . | Responders (n = 17) . | Nonresponders (n = 21) . |
|---|---|---|
| Median age (range), y | 62 (40-80) | 60 (41-76) |
| Males, n (%) | 15 (88.2) | 15 (71.4) |
| Prior therapy/disease status | ||
| Median no. of prior treatment regimens (range) | 2 (1-4) | 3 (1-6) |
| Refractory to last line of therapy, n (%) | 3 (17.6) | 13 (61.9) |
| Histology, n (%) | ||
| FL | 10 (58.8) | 8 (38.1) |
| MCL | 6 (35.3) | 7 (33.3) |
| DLBCL | 1 (5.9) | 4 (19.0) |
| Other (1 immunocytoma, 1 marginal zone lymphoma) | 0 | 2 (9.5) |
| Dose level, µg/m2per d | ||
| 5 | 0 | 2 |
| 15 | 1 | 8 |
| 30 | 0 | 2 |
| 60 | 14 | 8 |
| 90 | 2 | 1 |
| Treated at target dose, n (%), µg/m2 per d | ||
| <60 | 1 (5.9) | 12 (57.1) |
| ≥60 | 16 (94.1) | 9 (42.9) |
| Median treatment duration (range), d | 57 (4-85) | 31 (1-87) |
| Median no. of treatment cycles (range) | 1 (1-2) | 1 (1-3) |